BMJ1d
How the type of risk reduction influences required sample sizes in randomised clinical trials
Department of Internal Medicine, Division of Rheumatology, University of Maastricht, Maastricht, The Netherlands Correspondence to: Professor D van der Heijde Department of Internal Medicine, Division ...
BMJ2d
Studies with pain rating scales.
Good correlation has been shown between pain scores derived from 4 different rating scales. The correlation was maintained when presentation of the scales was separated by a series of questions and by ...
BMJ3d
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical ...
BMJ8d
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis
Objectives To evaluate the incidence of infection in patients with active rheumatoid arthritis (RA) treated with baricitinib, an oral selective Janus kinase (JAK)1 and JAK2 inhibitor. Methods ...
BMJ12d
EULAR definition of difficult-to-treat rheumatoid arthritis
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be ...
BMJ11d
Plasma proteome profiling in giant cell arteritis
Objectives This study aimed to identify plasma proteomic signatures that differentiate active and inactive giant cell arteritis (GCA) from non-disease controls. By comprehensively profiling the plasma ...
BMJ6d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ9d
Targeting the IL-6–Yap–Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis
Objective We aimed to understand the role of the transcriptional co-factor Yes-associated protein (Yap) in the molecular pathway underpinning the pathogenic transformation of synovial fibroblasts (SF) ...
BMJ3d
Oral steroid in the treatment of carpal tunnel syndrome
Dr S M Wong, Department of Medicine, Prince of Wales Hospital, 30–32 Ngan Shing Street, Shatin, New Territories, Hong Kong, Special Administrative Region China A range of options are available for the ...
BMJ12d
Elevated EPSTI1 promote B cell hyperactivation through NF-κB signalling in patients with primary Sjögren’s syndrome
2 Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China Correspondence to Hua Chen, Department of Rheumatology and Clinical Immunology, Peking Union Medical ...
BMJ12d
POS0095 CaMK4 CONTROLS T REGULATORY CELL METABOLISM AND DEFINES THEIR FUNCTION AND STABILITY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Background Calcium/Calmodulin-dependent protein kinase IV (CaMK4) is a serine kinase expressed in CD4 T cells whom activity is increased in patients with active systemic lupus erythematosus (SLE). We ...
BMJ11d
Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study
Objective To investigate the rate of serious bacterial, viral or opportunistic infection in patients with rheumatoid arthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis factor inhibitors ...